Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Mississippi for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Mississippi only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Mississippi (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Matthew Cassell (NPI 1427269331)

Field	Value
Entity Type	Individual
Organization	Matthew Cassell
Address	1704 23rd Ave
City	Meridian
State	MS
ZIP	39301
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 24, 2007

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

This provider is a hematology & oncology physician with long tenure in Medicare billing, having an NPI enumerated on 2007-05-24 (~19 years ago), indicating nearly two decades of established billing history in the Medicare program. That tenure supports the volume of oncology infusion and monitoring services reflected in the claims mix and suggests an ongoing outpatient oncology practice rather than a newly established clinician.

Medicare is effectively the only public payer on file: the provider has Total Medicare revenue of $1.3M and no Medicaid billing on file, making the practice functionally single-payer from a public program perspective. Analysts should treat this profile as concentrated in Medicare fee-for-service activity rather than dual-payer operations or significant state-plan volume.

Revenue concentration is very high among a few drug administration codes: the precomputed top 3 Medicare codes account for 79.1% of this provider’s total Medicare revenue, driven principally by J9271 (pembrolizumab) at $576.2K (45.5% of total), J0897 (denosumab) at $240.8K (19.0%), and J1449 (eflapegrastim-xnst) at $184.8K (14.6%). This mix indicates that high-cost oncology biologics and supportive-care biologics dominate revenue rather than evaluation-and-management visits or routine lab testing.

Operationally, the CPT/HCPCS mix points to an infusion-centered oncology practice: high counts and revenue for drug injection codes (J9271, J0897, J1449) together with chemotherapy administration codes (96413, 96401, 96417, 96415) and infusion administration codes (96365, 96367, 96375) indicate regular IV and injectable therapy sessions and associated add-on infusion time. The presence of lab panels (80053, 85025, , ) and frequent phlebotomy () further supports ongoing treatment monitoring and survivorship follow-up in an outpatient infusion setting.

On competitive standing, the provider’s national ranks are mixed: for the largest revenue driver J9271 the provider is at the 55th percentile nationally (rank #806 of 1841), implying typical, unremarkable volume relative to peers for pembrolizumab; by contrast J0897 is at the 93th percentile (rank #678 of 10057) and J1449 is an outlier at rank #12 of 161 (93th percentile) indicating notably above-typical national volume for eflapegrastim-xnst. Other chemotherapy administration codes such as 96413 and 96417 also sit at high percentiles (94th and 96th respectively), which together signal above-typical chemotherapy/infusion throughput relative to many national peers.

There are clear statistical outliers in utilization patterns: J1449 is noted as "notably above typical national volume" (rank #12 of 161) and 96413 and 96417 are also described as "notably above typical national volume" or high percentile activity, while J2469 (palonosetron) appears as an "extreme outlier, far above typical national volume" (rank #26 of 2634). These flagged items suggest the provider administers certain supportive-care and novel biologic agents at substantially higher frequency than most peers.

The service mix includes routine evaluation-and-management visits but these are secondary to drug and infusion revenue: E/M codes 99213 and 99214 contribute relatively small shares ($31.4K and $40.1K respectively) compared with high-revenue drug codes, and ranks for those E/M codes are in the upper percentiles (95th and 88th), suggesting a steady panel of established patients being seen in clinic in support of infusion services rather than E/M revenue being the primary business driver.

Given Medicare-only public payer exposure and the concentration in a handful of high-cost oncology drugs, risk and revenue forecasting should focus on drug utilization and procurement patterns. Any payer negotiations, site-of-care analyses, or utilization management programs for oncology biologics in this market should consider the provider’s outsized reliance on J9271, J0897, and J1449, which together form 79.1% of Medicare revenue and therefore represent the majority of negotiable/monitorable spend.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,400	$40	$576.2K
J0897	Injection, denosumab, 1 mg	13,380	$20	$240.8K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	7,390	$30	$184.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	590	$90	$51.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	450	$90	$40.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	550	$60	$31.4K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	90	$150	$13.8K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	280	$50	$13.7K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	100	$120	$12K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	570	$20	$11.4K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Mississippi Distribution

Matthew Cassell — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Mississippi

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	10	16,700	$40	$1M
J1449	2	10	4,160	$30	$149.3K
J0897	11	110	3,030	$20	$95.7K
96413	8	70	100	$80	$22.6K
99214	865	4,110	170	$70	$21.9K
Q0138	4	10	42,590	$1	$20.6K
99232	1,218	1,490	100	$60	$12.9K
99223	695	1,220	50	$120	$10.4K
99213	323	4,000	100	$50	$10.3K
99215	324	900	40	$110	$9K

Showing 1–10 of 46

Related Providers

Other providers that share a Tax Identification Number (TIN) with Matthew Cassell, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jennifer Eubanks	MS	Hematology & Oncology Physician	$728.8K	$0
John Voss	MS	Hematology & Oncology Physician	$631.8K	$0
John Halbrook	MS	Hematology & Oncology Physician	$216.5K	$0

Nearby Providers

Other providers in the same ZIP code as Matthew Cassell, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Anderson Regional Medical Center	MS	General Acute Care Hospital	$0	$32.5M
Rush Medical Foundation	MS	General Acute Care Hospital	$0	$29.4M
Meridian Pediatric Extended Care LLC	MS	Pediatric Skilled Nursing Facility	$0	$9.3M
Lauderdale County Ems District	MS	Ambulance	$2.1M	$6.4M
Southern Home Private Care LLC	MS	Homemaker	$0	$6M
Kevin Douglas	MS	Orthodontics and Dentofacial Orthopedics Dentistry	$0	$5.9M
Douglas Orthodontics PLLC	MS	Orthodontics and Dentofacial Orthopedics Dentistry	$0	$5.7M
Anderson Regional Medical Center	MS	Rural Health Clinic/Center	$0	$5.4M
Laird Hospital, Inc	MS	Rural Health Clinic/Center	$0	$5.3M
Medical Foundation, Inc.	MS	Clinical Medical Laboratory	$1M	$4.2M

Matthew Cassell — Billing Profile & Reimbursement Data

Sign up for Matthew Cassell — Billing Profile & Reimbursement Data policy alerts

Matthew Cassell — Billing Profile & Reimbursement Data

Sign up for Matthew Cassell — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References